AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. HOOD
6. QCOM
7. ACN
8. AZN
9. ROIV
10. AAPL

Go back to AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
AbbVie (NYSE: ABBV) Delayed: 248.78 -7.68 (2.99%)
Previous Close $256.46    52 Week High $68.12 
Open $251.84    52 Week Low $50.71 
Day High $254.62    P/E 53.97 
Day Low $248.41    EPS $4.61 
Volume 5,570,371